Actinogen Medical Limited (ACW.AX)
| Previous close | 0.0910 |
| Open | 0.0910 |
| Bid | 0.0900 x 194091900 |
| Ask | 0.0950 x 380640100 |
| Day's range | 0.0890 - 0.0950 |
| 52-week range | 0.0400 - 0.1600 |
| Volume | |
| Avg. volume | 861,390 |
| Market cap | 171.594M |
| Beta (5Y monthly) | 2.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0050 |
| Earnings date | 22 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.15 |
- PR Newswire
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical trial of Xanamem in patients with early stages of Alzheimer's Disease (AD).
- PR Newswire
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will measure the effects of Xanamem on safety, cognitive performance and depression in patients who are inadequately treated by their anti-depressant medication and have both depressive symptoms and cognitive impairment.
- PR Newswire
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients
Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer's Disease (AD) biomarker study, which validates the Company's planned Xanamem program in AD.
